{
    "sponsor_name": "",
    "study_acronym": "",
    "tested_imp": "Apixaban",
    "comparative_drug": "Dalteparin",
    "study_type": "",
    "interventional_study_phase": "",
    "study_design": "",
    "aim_of_study": "",
    "target_disease": "",
    "type_of_randomization": "",
    "randomization_stratification": [],
    "apixaban_dosing": "No dose adjustment for mild/moderate renal impairment; use with caution in severe renal impairment; VKA preferred over LMWH/DOACs if creatinine clearance <30 mL/min.",
    "dalteparin_dosing": "Dose modifications per product label and investigator discretion; adjust by 500 IU or 1,000 IU increments/decrements based on weight, renal function, and clinical events (bleeding or thrombosis).",
    "apixaban_supply_form": "",
    "dalteparin_supply_form": "",
    "scheduled_visits": [],
    "primary_efficacy_outcome": "",
    "secondary_efficacy_outcomes": [],
    "primary_safety_outcome": "",
    "secondary_safety_outcomes": [],
    "maximum_sample_size_per_arm": 0,
    "recommended_inclusion_criteria": [],
    "recommended_exclusion_criteria": []
}